Eventide Asset Management, LLC Vectiv Bio Holding Ag Transaction History

Eventide Asset Management, LLC

$6.2 Billion
Q1 2024

Shares

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2023 May 15, 2023	BUY	$7.34 - $9.15 $1.98 Million - $2.47 Million	270,000 Added 7.93%	3,675,644 $31.3 Million
Q4 2022 Feb 13, 2023	BUY	$7.79 - $8.98 $8.31 Million - $9.58 Million	1,066,600 Added 45.6%	3,405,644 $29.5 Million
Q3 2021 Nov 15, 2021	SELL	$6.7 - $11.54 $15,966 - $27,499	-2,383 Reduced 0.1%	2,339,044 $17.6 Million
Q2 2021 Aug 16, 2021	BUY	$11.66 - $24.23 $27.3 Million - $56.7 Million	2,341,427 New	2,341,427 $26.6 Million

Others Institutions Holding VECT

# of Institutions

1

Shares Held

510K

Call Options Held

0

Put Options Held

0

Regency Capital Management Inc.\De

510K
Shares

$0
0.0% of portfolio

About VectivBio Holding AG

Ticker VECT
Exchange NASDAQ
Description
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with sho...

More about VECT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eventide Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eventide Asset Management, LLC with notifications on news.